| Phases | Total Enrollment |
|---|---|
| PHASE3 | 529388 |
| PHASE2 | 169108 |
| PHASE1 | 68180 |
Unleashing the power of data
In the year 2024, the landscape of clinical trials saw a significant enrollment trend across different phases. Phase III trials led the pack with a staggering 529,388 participants, showcasing the highest level of engagement and interest. Following closely behind, Phase II trials attracted 169,108 participants, while Phase I trials had 68,180 participants. This data highlights the progression of research and development efforts, with Phase III trials taking the lead in advancing potential treatments and therapies. The numbers speak volumes about the evolving dynamics of clinical research, with each phase playing a crucial role in the journey towards groundbreaking medical advancements.
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Healthcare Companies
Number of Employees for Top 10 Pharma Companies
Average Market Capitalization of Abbvie Annually
5 Year Trend in Market Capitalization for AbbVie
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters